A role for Apolipoprotein A-I in the pathogenesis of multiple sclerosis
Abstract
Apolipoprotein A1 (Apo A-I), the most abundant component of high-density lipoprotein (HDL), is an anti-inflammatory molecule, yet its potential role in the pathogenesis of multiple sclerosis (MS) has not been fully investigated. In this study, Western blot analyses of human plasma showed differential Apo A-I expression in healthy controls compared to MS patients. Further, primary progressive MS patients had less plasma Apo A-I than other forms of MS. Using experimental allergic encephalomyelitis (EAE) as a model for MS, Apo A-I deficient mice exhibited worse clinical disease and more neurodegeneration concurrent with increased levels of pro-inflammatory cytokines compared to wild-type animals. These data suggest that Apo A-I plays a role in the pathogenesis of EAE, a model for MS, creating the possibility for agents that increase Apo A-I levels as potential therapies for MS.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Altered cholesterol, HDL and LDL metabolism, gene variants of APOA1, APOB, and APOE4, and decreased ApoA1 levels have been implicated in other neurologic disorders.
“Altered cholesterol, HDL and LDL metabolism, gene variants of APOA1, APOB, and APOE4, and decreased ApoA1 levels have been implicated in other neurologic disorders [21–35].”
From Sterol and lipid analyses identifies hypolipidemia and apolipoprotein disorders in autism associated with adaptive functioning deficits (2021) · cites this paper as [27]
Cites
Control of Regulatory T Cell Development by the Transcription Factor <i>Foxp3</i>
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187 · see citing works
Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis
van der Fits, L., Mourits, S., Voerman, J. S. A., Kant, M., Boon, L., Laman, J. D., Cornelissen, F., Mus, A.-M. C., Florencia, E. F., Prens, E. P., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802999 · Cited by 2,202 · see citing works
The IL-23/IL-17 axis in inflammation
Iwakura, Y. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28508 · Cited by 1,046 · see citing works
Identification of autoantibodies associated with myelin damage in multiple sclerosis
Genain, C. P., Cannella, B., Hauser, S. L., & Raine, C. S. (1999) · Nature Medicine · doi:10.1038/5532 · Cited by 891 · see citing works
New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions
Hunter, C. A. (2005) · Nature reviews. Immunology · doi:10.1038/nri1648 · Cited by 847 · see citing works
Understanding the IL-23–IL-17 immune pathway
McKenzie, B. S., Kastelein, R. A., & Cua, D. J. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.10.003 · Cited by 761 · see citing works
Haas, J., Hug, A., Viehöver, A., Fritzsching, B., Falk, C. S., Filser, A., Vetter, T., Milkova, L., Korporal, M., Fritz, B., et al. (2005) · European Journal of Immunology · doi:10.1002/eji.200526065 · Cited by 450 · see citing works
Type II monocytes modulate T cell–mediated central nervous system autoimmune disease
Weber, M. S., Prod'homme, T., Youssef, S., Dunn, S. E., Rundle, C. D., Lee, L., Patarroyo, J. C., Stüve, O., Sobel, R. A., Steinman, L., et al. (2007) · Nature Medicine · doi:10.1038/nm1620 · Cited by 447 · see citing works
Chataway, J., Schuerer, N., Alsanousi, A., Chan, D., MacManus, D. G., Hunter, K., Anderson, V. M., Bangham, C. R. M., Clegg, S., Nielsen, C. F., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62242-4 · Cited by 444 · see citing works
Rubin, E. M., Ishida, B. Y., Clift, S., & Krauss, R. M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.2.434 · Cited by 274 · see citing works
Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis
Bernard, C. C. A., Johns, T. G., Slavin, A., Ichikawa, M., Ewing, C., Liu, J., & Bettadapura, J. (1997) · Journal of Molecular Medicine · doi:10.1007/s001090050092 · Cited by 270 · see citing works
Hong, J., Li, N., Zhang, X., Zheng, B. Q., & Zhang, J. Z. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502187102 · Cited by 264 · see citing works
Dubois, B., Masure, S., Hurtenbach, U., Paemen, L. R., Heremans, H., van den Oord, J., Sciot, R., Meinhardt, T., Hämmerling, G. J., Opdenakker, G., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6886 · Cited by 262 · see citing works
Barter, P. J., Brandrup-Wognsen, G., Palmer, M. K., & Nicholls, S. J. (2010) · Journal of Lipid Research · doi:10.1194/jlr.p002816 · Cited by 259 · see citing works
Fluoro-Jade: Novel Fluorochromes for Detecting Toxicant-Induced Neuronal Degeneration
Schmued, L. C., & Hopkins, K. J. (2000) · Toxicologic Pathology · doi:10.1177/019262330002800111 · Cited by 255 · see citing works
Berthou, L., Duverger, N., Emmanuel, F., Langouët, S., Auwerx, J. H., Guillouzo, A., Fruchart, J., Rubin, E. M., Denèfle, P., Staels, B., et al. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118687 · Cited by 248 · see citing works
Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis
Weinstock‐Guttman, B., Zivadinov, R., Mahfooz, N., Carl, E. M., Drake, A. S., Schneider, J., Teter, B. E., Hussein, S. M., Mehta, B. K., Weiskopf, M., et al. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-127 · Cited by 232 · see citing works
Burger, D., & Dayer, J. (2002) · Autoimmunity Reviews · doi:10.1016/s1568-9972(01)00018-0 · Cited by 202 · see citing works
Qi, X.-F., Zheng, L., Lee, K.-J., Kim, D.-H., Kim, C.-S., Cai, D.-Q., Wu, Z., Qin, J.-W., Yu, Y., & Sk, K. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.44 · Cited by 151 · see citing works
You, Y., Klistorner, A. I., Thie, J., & Graham, S. L. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7434 · Cited by 144 · see citing works
Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis.
Diem, R., Sättler, M. B., Merkler, D., Demmer, I., Maier, K., Stadelmann, C., Ehrenreich, H., & Bähr, M. (2004) · Brain : a journal of neurology · doi:10.1093/brain/awh365 · Cited by 144 · see citing works
COMBINING BETA INTERFERON AND ATORVASTATIN MAY INCREASE DISEASE ACTIVITY IN MULTIPLE SCLEROSIS
Salvatore, E., Morra, V. B., & Orefice, G. (2009) · Neurology · doi:10.1212/wnl.0b013e3181ab6e08 · Cited by 121 · see citing works
Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis
Paul, F., Waiczies, S., Wuerfel, J. T., Bellmann–Strobl, J., Dörr, J. R., Waiczies, H., Haertle, M., Wernecke, K. D., Volk, H., Aktaş, O., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001928 · Cited by 121 · see citing works
Zhou, B., Yuan, J., Zhou, Y., Ghawji, M., Deng, Y., Lee, A. J., Lee, A. J., Nair, U., Kang, A. H., Brand, D. D., et al. (2011) · Clinical Immunology · doi:10.1016/j.clim.2011.08.014 · Cited by 106 · see citing works
Self-citationEvidence for increased lipid peroxidation in multiple sclerosis
Toshniwal, P. K., & Zarling, E. (1992) · Neurochemical Research · doi:10.1007/bf00966801 · Cited by 97 · see citing works
Sex differences in cytokine responses to myelin peptides in multiple sclerosis
Pelfrey, C. M., Cotleur, A. C., Lee, J.-C., & Rudick, R. A. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00224-2 · Cited by 93 · see citing works
Axonal Damage in Multiple Sclerosis
Haines, J., Inglese, M., & Casaccia, P. (2011) · The Mount Sinai journal of medicine, New York · doi:10.1002/msj.20246 · Cited by 85 · see citing works
APOA1 polymorphism influences risk for early-onset nonfamiliar AD
Vollbach, H., Heun, R., Morris, C. M., Edwardson, J. A., McKeith, I. G., Jessen, F., Schulz, A., Maier, W., & Kölsch, H. (2005) · Annals of Neurology · doi:10.1002/ana.20593 · Cited by 75 · see citing works
Ehara, A., & Ueda, S. (2009) · ACTA HISTOCHEMICA ET CYTOCHEMICA · doi:10.1267/ahc.09018 · Cited by 73 · see citing works
Matthan, N. R., Giovanni, A., Schaefer, E. J., Brown, B. G., & Lichtenstein, A. H. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m200439-jlr200 · Cited by 72 · see citing works
Gajski, G., Garaj‐Vrhovac, V., & Oreščanin, V. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.03.013 · Cited by 67 · see citing works
Almolda, B., Costa, M., Montoya, M., González, B., & Castellano, B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027473 · Cited by 64 · see citing works
Bian, G., Wei, L., Shi, M., Wang, Y.-Q., Cao, R. Y., & Chen, L.-W. (2007) · Brain Research · doi:10.1016/j.brainres.2007.02.078 · Cited by 56 · see citing works
Sullivan, T. A., Geisert, E. E., Hines-Beard, J., & Rex, T. S. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.052 · Cited by 50 · see citing works
Neurodegeneration in multiple sclerosis involves multiple pathogenic mechanisms
Levin, M. C., Gardner, L. A., Douglas, J. N., Meyers, L., Lee, S., & Shin, Y. (2014) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s54391 · Cited by 49 · see citing works
Self-citationLovastatin induces the formation of abnormal myelin‐like membrane sheets in primary oligodendrocytes
Maier, O., Jonge, J. D., Nomden, A., Hoekstra, D., & Baron, W. (2008) · Glia · doi:10.1002/glia.20769 · Cited by 43 · see citing works
Autoantibodies to Non-myelin Antigens as Contributors to the Pathogenesis of Multiple Sclerosis
Levin, M. C. (2013) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000148 · Cited by 43 · see citing works
Self-citationAn organotypic spinal cord slice culture model to quantify neurodegeneration
Ravikumar, M., Jain, S., Miller, R. H., Capadona, J. R., & Selkirk, S. M. (2012) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2012.09.004 · Cited by 37 · see citing works
Mukherjee, R., Locke, K. T., Miao, B., Meyers, D. S., Monshizadegan, H., Zhang, R., Search, D. J., Grimm, D., Flynn, M. A., O’Malley, K. M., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.143271 · Cited by 36 · see citing works
Brain Glycolipids Suppress T Helper Cells and Inhibit Autoimmune Demyelination
Mycko, M. P., Sliwinska, B., Cichalewska, M., Ćwiklińska, H., Raine, C. S., & Selmaj, K. W. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0885-14.2014 · Cited by 28 · see citing works
Koutsis, G., Πάνας, Μ., Giogkaraki, E., Karadima, G., Sfagos, C., & Vassilopoulos, D. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458508097217 · Cited by 18 · see citing works
Interferon β1a Therapy Changes Lipoprotein Metabolism in Patients with Multiple Sclerosis
Sena, A., Pedrosa, R., Ferret-Sena, V., de Almeida, R. M. M., Andrade, M. L., Morais, M. G., & Couderc, R. (2000) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2000.030 · Cited by 18 · see citing works
Functional Recovery and Morphological Changes after Injury to the Optic Nerve
Sabel, B. A., & Aschoff, A. (2008) · Neuropsychobiology · doi:10.1159/000119001 · Cited by 16 · see citing works
Coyle, P. K. (2005) · Neurologic Clinics · doi:10.1016/j.ncl.2004.10.003 · Cited by 16 · see citing works
Gandhi, K. S., McKay, F. C., Diefenbach, E., Crossett, B., Schibeci, S. D., Heard, R. N., Stewart, G. J., Booth, D. R., & Arthur, J. W. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010484 · Cited by 15 · see citing works
COMBINING BETA INTERFERON AND ATORVASTATIN MAY INCREASE DISEASE ACTIVITY IN MULTIPLE SCLEROSIS
Markovic‐Plese, S., Jewells, V. L., & Speer, D. (2009) · Neurology · doi:10.1212/01.wnl.0000349667.27301.c8 · Cited by 14 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Grassi, S., Giussani, P., Mauri, L., Prioni, S., Sonnino, S., & Prinetti, A. (2019) · Journal of Lipid Research · doi:10.1194/jlr.tr119000427 · Cited by 169 · see citing works
The physiology of foamy phagocytes in multiple sclerosis
Grajchen, E., Hendriks, J. J. A., & Bogie, J. F. J. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0628-8 · Cited by 147 · see citing works
Dietary cholesterol promotes repair of demyelinated lesions in the adult brain
Berghoff, S. A., Gerndt, N., Winchenbach, J., Stumpf, S. K., Hosang, L., Odoardi, F., Ruhwedel, T., Böhler, C., Barrette, B., Stassart, R., et al. (2017) · Nature Communications · doi:10.1038/ncomms14241 · Cited by 151 · see citing works
Monitoring the Redox Status in Multiple Sclerosis
Tanaka, M., & Vécsei, L. (2020) · Biomedicines · doi:10.3390/biomedicines8100406 · Cited by 88 · see citing works
Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients
Fellows, K., Uher, T., Browne, R. W., Weinstock‐Guttman, B., Horáková, D., Posová, H., Vaněčková, M., Seidl, Z., Krásenský, J., Týblová, M., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m060970 · Cited by 68 · see citing works
Jorissen, W., Wouters, E., Bogie, J. F. J., Vanmierlo, T., Noben, J., Sviridov, D. O., Hellings, N., Somers, V. A., Valcke, R., Vanwijmeersch, B., et al. (2017) · Scientific Reports · doi:10.1038/srep43410 · Cited by 59 · see citing works
Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia
Boiko, A. S., Mednova, I. A., Kornetova, E. G., Semke, A. V., Bokhan, N. A., LOONEN, A. J. M., & Ivanova, S. А. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e02033 · Cited by 49 · see citing works
Ghaiad, H. R., Elmazny, A. N., Nooh, M. M., El‐Sawalhi, M. M., & Shaheen, A. A. (2019) · Journal of Advanced Research · doi:10.1016/j.jare.2019.10.012 · Cited by 38 · see citing works
Douglas, J. N., Gardner, L. A., Salapa, H. E., Lalor, S. J., Lee, S., Segal, B. M., Sawchenko, P. E., & Levin, M. C. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0647-y · Cited by 30 · see citing works
Self-citationAntigenicity of Bovine Pericardium Determined by a Novel Immunoproteomic Approach
Gates, K. V., Dalgliesh, A. J., & Griffiths, L. G. (2017) · Scientific Reports · doi:10.1038/s41598-017-02719-8 · Cited by 29 · see citing works
Importance of Apolipoprotein A-I in Multiple Sclerosis
Gardner, L. A., & Levin, M. C. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00278 · Cited by 27 · see citing works
Self-citationTierney, E., Remaley, A. T., Thurm, A., Jager, L. R., Wassif, C. A., Kratz, L. E., Bailey-Wilson, J. E., Bukelis, I., Sarphare, G., Jung, E. S., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01580-8 · Cited by 26 · see citing works
West, K. P., Cole, R. N., Shrestha, S., Schulze, K. J., Lee, S. E., Betz, J., Nonyane, B. A. S., Wu, L. S.-F., Yager, J. D., Groopman, J. D., et al. (2015) · Journal of Nutrition · doi:10.3945/jn.115.210682 · Cited by 22 · see citing works
Self-citationFunctional evolution of visual involvement in experimental autoimmune encephalomyelitis
Marenna, S., Huang, S., Castoldi, V., d’Isa, R., Costa, G. D., Comı, G., & Leocani, L. (2020) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/2055217320963474 · Cited by 20 · see citing works
Apolipoprotein A (ApoA) in Neurological Disorders: Connections and Insights
Rajha, H. E., Hassanein, A., Mesilhy, R., Nurulhaque, Z., Elghoul, N., Burgon, P. G., Saady, R. M. A., & Pedersen, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167908 · Cited by 15 · see citing works
Jorissen, W., Vanmierlo, T., Wens, I., Somers, V. A., Wijmeersch, B. V., Bogie, J. F. J., Remaley, A. T., Eijnde, B. O., & Hendriks, J. J. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010193 · Cited by 15 · see citing works
Ortí, J. E. D. L. R., Armero, J. L. P., Cuerda‐Ballester, M., Sanchis-Sanchis, C. E., Navarro-Illana, E., Lajara-Romance, J. M., Benlloch, M., Cerón, J. M. C., Tvarijonaviciute, A., & Proaño, B. (2023) · Foods · doi:10.3390/foods12203730 · Cited by 12 · see citing works
Mantash, S., Aboulouard, S., Dakik, H., Zirem, Y., Ziane-Chaouche, L., Nehme, A., Mallah, K., El-Kurdi, M., Ramadan, N., Fournier, I., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02286-9 · Cited by 10 · see citing works
Liu, F., Huang, T., Wang, B., Wang, C., & Guo, S. (2022) · Neuroscience Letters · doi:10.1016/j.neulet.2022.136546 · Cited by 7 · see citing works
Protective Role of High-Density Lipoprotein in Multiple Sclerosis
Damiza-Detmer, A., Pawelczyk, M., & Glabinski, A. R. (2024) · Antioxidants · doi:10.3390/antiox13111276 · Cited by 7 · see citing works
Ursodeoxycholic acid alleviates multiple sclerosis via TGR5-dependent microglial regulation in mice
Sonoda, Y., Aizawa, F., Tomochika, N., Miyauchi, K., Nishibashi, A., Takahashi, S., Kosako, H., Tanida, S., Yagi, K., Niimura, T., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177941 · Cited by 4 · see citing works
Samangooei, M., Farjam, M., Etemadifar, M., Taheri, A., Meshkibaf, M. H., Movahedi, B., Niknam, Z., & Noroozi, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-06322-4 · Cited by 4 · see citing works
The Role of Lipid Alteration in Multiple Sclerosis
Damiza-Detmer, A., Pawelczyk, M., & Glabinski, A. R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020812 · Cited by 3 · see citing works
Saha, S. G., Mukherjee, S., Guha, G., & Mukhopadhyay, D. (2020) · Journal of Proteins and Proteomics · doi:10.1007/s42485-020-00036-9 · Cited by 2 · see citing works
Plasma lipid profiles and homocysteine levels in anti-N-methyl-D-aspartate receptor encephalitis
Wang, Z., Qiao, S., Wang, L., Wang, K., Zhang, R., Jin, Y., Wu, H.-K., & Liu, X. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1148450
Mehana, N. A., Ghaiad, H. R., Nooh, M. M., Amer, M. A., El-Ghoneimy, L. T., & Safwat, M. H. (2026) · Bioscience Reports · doi:10.1042/bsr20260065
- Authors
- Meyers, L., Groover, C. J., Douglas, J., Lee, S., Brand, D., Levin, M. C., & Gardner, L. A.
- Affiliations
- Memphis VA Medical Center (US)
- University of Tennessee Health Science Center (US)
- Corresponding author
- Gardner, Lidia A.
- Venue
- Journal of Neuroimmunology
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 277
- Issue
- 1-2
- Pages
- 176-185
- ISSN
- 0165-5728 (ISSN-L)
- OpenAlex
- W1988076778
- Cited by
- 27
- References
- 46
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 3 · 2016: 2 · 2015: 3
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Neuroimmunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Multiple Sclerosis Society (A13-04262-001)
- VA Merit Review Award (BX001996-01A1)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Keywords
- apolipoprotein A-I, multiple sclerosis, high-density lipoprotein, experimental autoimmune encephalomyelitis, primary progressive multiple sclerosis, neurodegeneration, inflammatory cytokines, pathogenesis
- MeSH terms
- Adult, Animals, Disease Models, Animal, Encephalomyelitis, Autoimmune, Experimental, Evoked Potentials, Visual, Female, Fluoresceins, Freund's Adjuvant, Gene Expression Regulation, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Multiple Sclerosis, Peptide Fragments, Electrophoresis, Gel, Two-Dimensional, Case-Control Studies, Cytokines, Apolipoprotein A-I, Mice, Myelin-Oligodendrocyte Glycoprotein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
